Infectious Disease Molecular Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Infectious disease molecular diagnostics represents the largest application segment within the overall molecular diagnostics market, which is valued at approximately $23 billion globally in 2025. These tests enable healthcare providers to identify specific pathogens with high sensitivity and specificity, supporting more targeted treatment decisions and faster outbreak response. The market encompasses a wide range of testing platforms, reagents, and software used in hospitals, public health laboratories, and commercial testing facilities.

• •Infectious disease testing accounts for roughly 60% of the broader molecular diagnostics market share
• •The segment spans bacterial, viral, fungal, and parasitic testing across clinical and public health settings
• •Technology platforms include PCR-based systems, isothermal amplification methods, and next-generation sequencing

Government initiatives and public health campaigns have significantly expanded access to molecular diagnostic testing, particularly in emerging markets where healthcare infrastructure continues to develop. The increasing global burden of infectious diseases, including antimicrobial-resistant pathogens and emerging infectious threats, has created sustained demand for rapid and accurate diagnostic solutions. Technological advancements that reduce turnaround time, improve multiplexing capabilities, and enable point-of-care deployment are further accelerating adoption across clinical settings.

• •Expanding government-funded screening and surveillance programs in both developed and developing regions
• •Rising prevalence of infectious diseases and growing concern over antimicrobial resistance
• •Improvements in test automation, portability, and cost-effectiveness driving broader clinical utilization

The market is typically segmented by product type, including instruments, reagents and kits, and software, as well as by technology platform and disease indication. Emerging infectious diseases represent a notable sub-segment, with dedicated molecular tests for novel and re-emerging pathogens drawing increasing investment. Geographically, North America and Europe lead in market revenue due to established healthcare infrastructure and higher testing adoption rates, while the Asia-Pacific region is expected to see relatively faster growth as diagnostic access expands.

• •Reagents and consumables typically represent the largest revenue component within the product mix
• •Emerging infectious disease molecular diagnostics is a distinct growth segment within the broader market
• •Asia-Pacific is projected as a high-growth region driven by healthcare modernization and increased disease surveillance investment

What are the recent trends and outlook?

Integration of molecular diagnostics with digital health platforms and artificial-driven result interpretation is expected to shape the next phase of market development. Multiplex testing panels that detect multiple pathogens simultaneously are gaining adoption for their efficiency in managing outbreaks and routine clinical diagnostics. Continued emphasis on pandemic preparedness and supply chain resilience is likely to sustain government investment in molecular diagnostic capacity through the end of the decade.

• •Multiplex pathogen panels and syndromic testing approaches are expanding beyond traditional single-target assays
• •Point-of-care molecular testing is increasingly bridging the gap between centralized laboratory analysis and rapid clinical decision-making
• •Long-term market growth will be supported by global health security priorities and ongoing investment in diagnostic preparedness